<?xml version='1.0' encoding='utf-8'?>
<document id="19309423"><sentence text="Onychomycosis and diabetes." /><sentence text="This study aims to discuss factors specific to diabetics in the diagnosis and treatment of onychomycosis" /><sentence text="" /><sentence text="Onychomycosis has the potential to cause severe complications in diabetics and should be treated promptly" /><sentence text=" The existence of comorbid conditions and potential for drug-drug interactions complicates the selection of an appropriate treatment regimen" /><sentence text=" The role of Candida in onychomycosis is controversial but may be of increased significance in the diabetic population due to an underlying vulnerability to this organism" /><sentence text="" /><sentence text="Terbinafine is an excellent choice in diabetics due to its low risk of drug-drug interaction and proven efficacy against the typical pathogens that cause onychomycosis"><entity charOffset="0-11" id="DDI-PubMed.19309423.s8.e0" text="Terbinafine" /></sentence><sentence text=" Itraconazole, while an effective treatment for onychomycosis, is not a first-choice therapy due to its black-box cardiac warning and numerous drug interactions"><entity charOffset="1-13" id="DDI-PubMed.19309423.s9.e0" text="Itraconazole" /></sentence><sentence text=" Larger studies are needed in diabetics to determine the frequency of candidal nail infections" /><sentence text="" /></document>